Atriva Therapeutics, a privately held biotechnology company based in Germany that is focused on developing antiviral therapies for the treatment of influenza and other viral diseases, has closed a continuation to their seed round  with the participation of InSynchrony Ventures, InSymbiosis’ investment partner, as well as other investors. The capital will be used to advance their lead project ATR-002 indication influenza which is 12 months away from clinical development and InSymbiosis will provide development support for the program.

Atriva is developing the next generation of Antiviral Therapies based on MEK Inhibitors that have a high potential as efficacious and safe antiviral drugs to address the urgent need for novel, active anti-viral drugs with favorable benefit-risk profile. Atriva was founded in 2015 by a group of renowned virologist and European serial entrepreneurs and experts from life-science industry.

If you wish to learn more about Atriva Therapeutics, please visit their website:

http://www.atriva-therapeutics.com/
atriva_therapeutics_pngThe InSymbiosis Team